Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX 1 and 4 inhibitor, GKT137831, will be presented at Kidney Week 2012 (San Diego, October 30 - November 4).

The Phase I data will be presented in the Pharmacokinetics (PK)/ Pharmacodynamics (PD) session:

Friday, November 2, 2012, 10.00 AM -12.00 PM

PosterBoard# FR-PO831; Abstract# 2279

Safety and Pharmacokinetics of Single and Multiple Doses of a First in Class Dual NADPH Oxidase 1 and 4 Inhibitor Administered Orally in Health Subjects

Preliminary Phase I results released earlier this year showed that GKT137831 is safe and well tolerated following oral administration of single doses in 36 healthy subjects. Genkyotex plans to advance GKT137831 into a Phase II trial in patients with diabetic nephropathy.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Higher levels of physical activity associated with reduced risk of cardiovascular events in adults with CKD